MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1

BACKGROUND: Ovarian cancer (OC) is the most lethal gynecological malignancy and the second leading cause of cancer-related death in women. Treatment with PARP inhibitors (PARPi), such as Olaparib, has been recently introduced for OC patients, but resistance may occur and underlying mechanisms are st...

Descripción completa

Detalles Bibliográficos
Autores principales: Vescarelli, Enrica, Gerini, Giulia, Megiorni, Francesca, Anastasiadou, Eleni, Pontecorvi, Paola, Solito, Luciana, De Vitis, Claudia, Camero, Simona, Marchetti, Claudia, Mancini, Rita, Benedetti Panici, Pierluigi, Dominici, Carlo, Romano, Ferdinando, Angeloni, Antonio, Marchese, Cinzia, Ceccarelli, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939329/
https://www.ncbi.nlm.nih.gov/pubmed/31898520
http://dx.doi.org/10.1186/s13046-019-1490-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939329/
https://www.ncbi.nlm.nih.gov/pubmed/31898520
http://dx.doi.org/10.1186/s13046-019-1490-7

Ejemplares similares